

Index of subjects Volume 7 (1996)

A

α -interferon

- as a treatment for patients with metastatic colorectal carcinoma 575
- as a treatment for patients with metastatic carcinoid and malignant endocrine pancreatic tumours (Short report) 208
- as a treatment for patients with neuroendocrine gastrointestinal tumours (Review) 459
- in combination therapy with 5-fluorouracil (Short report) 208, 575

acute aortic thrombosis

- in patients with small-cell lung carcinoma (Letter to the editor) 321

acute lymphoblastic leukemia

- meta-analysis and prospective meta analysis in clinical research (Arena) 1009
- monitoring L-asparagine depletion in plasma and cerebro-spinal fluid 725
- secondary malignancies (Letter to the editor) 322
- successful treatment (Letter to the editor) 322

acute myelogenous leukemia

- probability of long-term disease-free survival 933

adenocarcinoma

- of the esophagus or esophago-gastric junction area (Short report) 533

adenoid cystic carcinoma

- in head and neck (Short report) 867
- treatment with mitoxantrone (Short report) 867

ADEPT

- used in cancer drug therapy (Special article) 445

adjuvant chemo-tamoxifen therapy

- as a treatment for patients with early breast cancer 239
- risk of new primaries 239

adjuvant chemotherapy

- as a treatment for patients with breast cancer (Short report) 745
- as a treatment for patients with early breast cancer 239
- long-term results in stage I and II Hodgkin's disease 145
- risk of new primaries 239

adjuvant surgery

- as a treatment for patients with small-cell lung cancer 303

adjuvant systemic treatment

- in breast cancer (Editorial) 221

adjuvant tamoxifen

- as a treatment for patients with early breast cancer 239
- risk of new primaries 239

adjuvant therapy

- as a treatment for patients with breast cancer 245
- as a treatment for patients with colon cancer (Short report) 412
- effect of occurrences in second malignancies 245
- multifocal leukoencephalopathy (Short report) 412

adjuvant treatment

- in node-negative and estrogen receptor-negative breast cancer 481

adoptive cellular therapy

- as a treatment for patients with metastatic renal cell cancer (Review) 887

advanced breast cancer

- mobilisation kinetics of primitive haemopoietic cells following G-CSF 1051
- treatment with doxorubicin and paclitaxel 687
- treatment with intravenous infusion of 5-fluorouracil 807

advanced colorectal carcinoma

- factors influencing response rates (Arena) 901
- treatment with oxaliplatin (Short report) 95

advanced multiple myeloma

- use of oral idarubicin and prednisone (Letter to the editor) 537

advanced non-small-cell lung cancer

- use of radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy 139

advanced ovarian cancer

- single agent activity of oxaliplatin 1065

advanced pancreatic adenocarcinoma

- treatment with 5-fluorouracil, leucovorin and cisplatin 173

advanced salivary gland carcinoma

- treatment with chemotherapy (Short report) 640
- treatment according to CAP regimen (Short report) 640

advanced squamous cell carcinoma of head and neck

- phase II trial (Letter to the editor) 539
- treatment with 13-cis retinoic acid plus interferon- α (Letter to the editor) 539

advanced stages

- of Hodgkin's disease (Review) S4: 99

aetiology

- in Hodgkin's disease (Review) S4: 5

AIDS

- related to non-Hodgkin's lymphoma 1029

akathisia

- associated with prochlorperazine as an antiemetic (Editorial) 103

allogeneic blood progenitor cells

- transplantation of (Review) S2: 41

allogeneic bone marrow transplantation

- schedules in high-dose chemotherapy 83

allogeneic transplantation

- of cord blood (Review) S2: 47
- of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia (Review) S2: 19

American perspective

- on clinical benefit (Editorial) 335

AML

- cytokine production 397
- treatment with interleukin 10 397

anaplastic

- carcinoma of the thyroid (Clinical case) 739

angiogenesis

- bFGF and VEGF 843

angiogenesis inhibitors

- clinical studies (Editorial) 441
- phase I study 491
- tecogalan sodium 491

animal study

- stem cells in mice (Review) S2: 15

antibodies

- as anticancer agents (Special article) 445

anticancer chemotherapy

- as a treatment for patients with breast cancer 165

- multicentre phase II study 165
- antineoplastic agents
 - use in the therapy of HIV-related non-Hodgkin's lymphoma 1029
- antiprogesterins
 - in the human breast cell line T-47D 391
 - induction of TGF-beta 391
- antiretroviral therapy
 - use in HIV-related non-Hodgkin's lymphoma 1029
- antithrombin III
 - interaction between HRT and tamoxifen 671
- application schedules
 - in patients with bone marrow transplantation 83
- aPTT
 - pentosan 939
- aromatase inhibitors
 - as a treatment of patients with advanced breast cancer 471
 - as a treatment of patients with breast cancer (Short report) 99
 - new generation of (Editorial) 433
- arthralgia
 - in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
- attitudes
 - toward euthanasia 907
- autograft
 - hematopoietic recovery 719
- autologous blood stem cell transplantation
 - for patients with chronic lymphocytic leukemia 373
 - long-term survival 373
- autologous bone marrow transplantation
 - in patients with acute myeloid leukemia 933
 - in patients with breast cancer (Review) S2: 31
- autologous transplantation
 - hematopoietic stem cells (Review) S2: 5
 - of Ph1-negative blood progenitor cells (Review) S2: 19
 - in patients with chronic myelogenous leukaemia (Review) S2: 19
- B**
- B-cell lymphoma
 - new classification (Review) S6: 3
 - classification and therapeutic implications (Review) S6: 35
- B-CLL
 - evolution into chronic lymphocytic leukaemia (Clinical case) 953
- bax
 - in relation to Bcl-2 in breast cancer (Rapid publication) 129
- bcl-1
 - involvement of the CCND1 gene 251
- bcl-2
 - clinical significance for patients with diffuse large B-cell lymphomas 1023
 - expression of Bax in breast cancer (Rapid publication) 129
- bcl-2 rearrangement
 - detection of cells (Rapid publication) 793
 - in patients with non-Hodgkin's lymphoma (Rapid publication) 793
- Ber-H2/saporin
 - for clinical use in Hodgkin's disease (Review) S4: 135
- bilharziasis
 - treatment with combination therapy (Short report) 751
- biliary cancer
 - and the quality of life 593
- survival improvement in patients 593
- biochemical modulation
 - as a treatment for patients with advanced colorectal cancer 581
 - of 5-FU with leucovorin 581
- biochemotherapy
 - treatment of patients with metastatic melanoma 827
- biological markers
 - diagnostic and prognostic value 607
 - in neuroblastoma 607
- biology
 - report on the workshop of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995 (Symposium article) S4: 45
- bioreductives
 - as a new approach in cancer chemotherapy (Special article) 445
- biotherapy
 - in combination with chemotherapy 827
 - treatment of patients with metastatic melanoma 827
- bispecific antibodies
 - treatment of Hodgkin's disease (Review) S4: 143
- bladder cancer
 - treatment with combination chemotherapy (Short report) 751
- bone marrow
 - analysis of prognostic factors associated with hematopoietic recovery 719
 - autotransplant of progenitor cells 719
 - study of hematopoietic stem cells (Review) S2: 5
- bone marrow stromal cultures
 - as a therapy for patients with advanced breast cancer 1051
- bone marrow transplantation
 - and high-dose chemotherapy 151
 - as a treatment in patients with Hodgkin's disease 151
 - use in therapy of low-grade non-Hodgkin's lymphomas (Review) S6: 13
- bone metastases
 - treatment with prednisone (Letter to the editor) 640
- bone mineral density
 - effect of tamoxifen and hormone replacement therapy 671
- bone sarcomas
 - treatment with neoadjuvant chemotherapy (Short report) 864
- breast cancer
 - antiprogesterins 391
 - carcinomatous meningitis (Review) 773
 - detection of 619
 - dose-intensive chemotherapy for 35
 - effects of adjuvant systemic treatment (Editorial) 221
 - effects of fadrozole versus tamoxifen 471
 - effects of prednisone combined with CMF 245
 - efficacy and safety of docetaxel as first-line treatment 165
 - expression of Bax in relation to Bcl-2 (Rapid publication) 129
 - hormonal replacement therapy 655
 - induction of TGF-beta 391
 - locally advanced 165
 - metastatic 165, 465, 487
 - node-negative 481
 - phase II trial (Short report) 857
 - pretreated 55
 - psychological distress (Letter to the editor) 977
 - role of maspin gene 619
 - treatment with adjuvant chemotherapy 239, 745 (Short report)
 - treatment with adjuvant therapy 245, 695, 977 (Letter to the editor)

- treatment with CMF-inf (Short report) 409
- treatment with 8-chloroadenosine 3',5' monophosphate 291
- treatment with paclitaxel and vinorelbine (Short report) 857
- treatment with tamoxifen 239
- use of aromatase inhibitors in treatment of patients with (Short report) 99
- breast neoplasms
 - dose intensification (Review) S2: 31
 - peripheral blood progenitor cells (Review) S2: 11
- C
- CA 125
 - progression of ovarian carcinoma 361
- cancer
 - CARES-SF 381
 - chemotherapy (Special article) 445
 - elderly patients 677
 - euthanasia 907
 - incidence and mortality 497
 - palliative and supportive care (Arena) 135
 - patient perceptions of the effects of chemotherapy 189
 - quality of life 381
 - research (Editorial) 439
 - treatment (Editorial) 657
 - treatment with pentosan 939
 - use of hypnotics (Short report) 855
- cancer drug development
 - phase I trials (Commentary) 567
- cancer pain
 - use of methadone 613
- cancer therapy
 - use of the nuclear matrix (Review) 659
- cancer vaccines
 - immune monitoring of (Commentary) 667
 - peptide-based (Review) 339
 - recognition of tumour-associated antigens (Review) 339
- CAP regimen
 - as a treatment for patients with advanced salivary gland carcinoma (Short report) 640
- carboplatin
 - as a treatment for patients with locally advanced carcinoma of the cervix 511
 - as a treatment for patients with good-risk metastatic non-seminomatous germ cell tumours 1015
 - as a treatment for patients with small-cell lung cancer 365
 - comparison with cisplatin 365
 - in combination chemotherapy of non-seminomatous germ cell tumours (Editorial) 989
 - in combination with teniposide and vincristine 365
- carcinoid
 - treatment with a combination of interferon- α -2a and 5-fluorouracil (Short report) 208
- carcinoids
 - as part of the neuroendocrine gastrointestinal tumours (Review) 453
- carcinomatous meningitis
 - in solid tumours (Review) 773
- cardiac sequelae
 - after treatment for Hodgkin's disease 257
 - increased risks in females 257
- cardiotoxicity
 - of 5-fluorouracil 731
 - of combined doxorubicin and paclitaxel in advanced breast cancer 687
- CARES-SF
 - and the quality of life 381
 - validity and reliability 381
- causes of death
 - of patients with Hodgkin's disease (Review) S4: 115
- CCND1
 - in hairy cell leukemia 251
- cDNA libraries
 - its role for analysis of Hodgkin's disease (Review) S4: 35
- CD30
 - ligand interaction in Hodgkin's lymphoma (Symposium article) S4: 45
- CD34+ blood cells
 - allogeneic transplantation (Review) S2: 41
 - transduction of (Review) S2: 53
- CD34+ cells
 - loss from (Review) S2: 47
 - positive selection of ex vivo expansion of (Review) S2: 11
- cell culture model
 - influence of 5-FU 731
- cell cycle regulation
 - fundamental research on (Commentary) 343
- cell transplantation
 - as a treatment for patients with inoperable relapse of nuchal liposarcoma (Letter to the editor) 871
- cervical cancer
 - treatment with concurrent chemo- and radiotherapy 511
- CGS 16949A
 - treatment in women with advanced breast cancer 471
 - versus tamoxifen 471
- challenges
 - for the future in ovarian cancer research 9
- chemoradiotherapy
 - treatment for patients with small-cell lung cancer 303
- chemoprevention
 - instead of cancer chemotherapy (Special article) 445
- chemotherapy
 - alone in treatment of early stage Hodgkin's disease (Review) S4: 85
 - and G-CSF for patients with advanced breast cancer 1051
 - as a treatment
 - for elderly patients (Short report) 966
 - for patients with
 - advanced bilharzial bladder carcinoma (Short report) 751
 - advanced breast cancer 807
 - advanced colorectal cancer (Arena) 901, (Short report) 961
 - advanced endometrial cancer (Short report) 861
 - advanced pancreatic cancer 593
 - advanced salivary gland carcinoma (Short report) 640
 - advanced testicular choriocarcinoma (Letter to the editor) 536
 - biliary cancer 593, (Letter to the editor) 644
 - bone sarcomas (Short report) 864
 - breast cancer 35, S2: 31 (Review)
 - carcinoma of the thyroid (Clinical case) 739
 - cervical cancer 511
 - chronic myelogenous leukaemia (Review) S2: 19
 - esophageal carcinoma 353

- 5-FU-refractory pancreas cancer (Rapid publication) 347
- head and neck cancer (Review) 15
- Hodgkin's disease 257, (Special article) 555, (Review) S4: 109, (Clinical case) 1071
- metastatic melanoma 827
- non-Hodgkin's lymphomas (Short report) 966, S6: 13 (Review)
- non-seminomatous germ cell tumours 1015, (Editorial) 989
- non-small-lung cancer 311, (Short report) 414, 517, (Short report) 637, 821
- ovarian carcinoma 65, 705
- solid tumours (Review) S2: 23
- testicular cancer 31
- combined with radiotherapy 919
- CPT-11 dosage 837
- for bulky or advanced Hodgkin's disease (Review) S4: 105
- haemopoietic stem cells (Review) S2: 5
- historical control studies 355
- improvement of quality of life 593
- in advanced Hodgkin's disease (Review) S4: 95
- in combination with biotherapy 827
- low-dose continuous intravenous infusion of 5-fluorouracil 807
- low-dose cisplatin- or non-cisplatin 505
- neoadjuvant (Short report) 864, (Letter to the editor) 871
- occurrence of cardiopulmonary sequelae 257
- optimum anti-emetic therapy 277
- patient perceptions of side effects 189
- peripheral blood progenitor cell transplantation (Introduction) S2: 1
- phase I study (Short report) 311, 314
- phase II study (Rapid publication) 347, (Short report) 637, (Short report) 861
- phase III randomised trial 821
- prolongment of survival 593
- pulmonary toxicity (Short report) 973
- purging of peripheral blood progenitor cells (Review) S2: 11
- randomized trials 355
- childhood
- present and future strategies of Hodgkin's lymphoma's treatment (Review) S4: 73
- cholesterol
- interaction between HRT and tamoxifen 671
- choriocarcinoma
- diagnosis of residual disease (Short report) 416
- diagnosis of tumour emboli (Short report) 416
- positron emission tomography (Short report) 416
- chromogranin A
- in neuroendocrine gastrointestinal tumours (Review) 454
- chronic lymphocytic leukemia (CLL)
- long-term survival 373
- purine analogs (Review) S6: 27
- treatment with 2-CdA-therapy 373
- chronic myelogenous leukaemia
- mobilization/transplantation of Ph1-negative blood progenitor cells (Review) S2: 19
- CHVmP
- as a treatment for patients with non-Hodgkin's lymphomas 925
- cisplatin
- as a treatment for patients with
- advanced endometrial cancer (Short report) 861
- advanced pancreatic adenocarcinoma 173
- good-risk metastatic non-seminomatous germ cell tumours 1015
- non-small cell lung cancer and malignant melanoma (Short report) 1080
- ovarian cancer 65, 1077 (Short report)
- small-cell lung cancer 365, 747 (Short report)
- compared to carboplatin 365
- in combination with teniposide and vincristine 365
- inducement of delayed emesis 945
- phase III study in non-small-cell lung cancer 517
- cisplatin resistance
- in testicular cancer 31
- cladribine
- treatment for patients with non-Hodgkin's lymphoma (Rapid publication) 793
- classification systems
- of mantle-cell lymphoma (Review) S6: 35
- clinical
- research of ovarian cancer 9
- studies with angiogenesis (Editorial) 441
- trials in Hodgkin's disease (Review) S4: 109, 127
- clinical benefit
- an American perspective (Editorial) 335
- an European perspective (Editorial) 333
- for patients with pancreatic cancer (Rapid publication) 347
- phase II trial of gemcitabine (Rapid publication) 347
- Clinical cases
- anaplastic
- carcinoma of the thyroid 739
- B-CLL
- evolution into chronic lymphocytic leukaemia 953
- chemotherapy
- as a treatment for patients with carcinoma of the thyroid 739
- as a treatment for patients with Hodgkin's disease 1071
- clonality
- in B-cell lymphoma 953
- corticosteroids
- in granulosa cell tumour of the ovary 521
- follicular lymphoma
- histological transformation 849
- granulosa cell tumour
- of the ovary 521
- Hodgkin's disease
- complications by second cancers 405
- meningeal localization in a patient 1071
- immunogenotype
- in lymphocytic leukemia 953
- immunophenotype
- in lymphocytic leukemia 953
- leukaemia
- complicating Hodgkin's disease 405
- lung cancer
- role of surgery in small-cell 303
- lymphoma
- clonal analysis 953
- evolution into lymphocytic leukemia 953
- meningeal lymphoma
- in patients with Hodgkin's disease 1071

- prognosis
 - for patients with follicular lymphoma 849
 - radiation
 - therapy for patients with anaplastic carcinoma of the thyroid 739
 - radiotherapy
 - as a treatment for patients with Hodgkin's disease 1071
 - second cancers
 - in Hodgkin's disease 405
 - leukemia 405
 - small-cell lung cancer
 - the role of surgery 303
 - thyroid cancer
 - anaplastic 739
 - transformation
 - of indolent lymphoma 849
 - treatment
 - of patients with follicular lymphoma 849
 - of patients with granulosa cell tumour of the ovary 521
 - tumour lysis syndrome
 - review of literature 631
 - clonal evolution
 - and tumour heterogeneity (Review) 121
 - clonal heterogeneity
 - analysis of Hodgkin's disease (Review) S4: 35
 - clonality
 - and tumour heterogeneity (Review) 121
 - in B-cell lymphoma (Clinical case) 953
 - of Hodgkin and Reed-Sternberg cells (Review) S4: 11
 - clubbing
 - in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
 - CMF
 - as a treatment for patients with breast cancer (Short report) 409
 - combined with adjuvant prednisone 245
 - effects of treatment in patients with breast cancer 245
 - effects on patterns of relapse 245
 - infusional (Short report) 409
 - cognitive function
 - effect of hypnotics discontinuation (Short report) 855
 - colon cancer
 - multifocal leukoencephalopathy (Short report) 412
 - treatment with levamisole adjuvant therapy (Short report) 412
 - colony stimulating factors
 - treatment of patients with HIV-related non-Hodgkin's lymphomas (Arena) 233
 - colorectal cancer
 - magnetic resonance spectroscopy 47
 - phase I study (Short report) 317
 - prolonged continuous hepatic artery infusion with interleukin-2 (Short report) 317
 - TCNU (Letter to the editor) 211
 - treatment with bFGF and VEGF 843
 - treatment with 5-fluorouracil 41, (Editorial) 531
 - treatment with 5-fluorouracil plus α -interferon 575
 - unresectable liver metastases (Short report) 317
 - colorectal cancer (advanced)
 - phase II trial 581
 - randomised trial (Short report) 961
 - treatment with 5-fluorouracil plus oral leucovorin 581, (Short report) 961
 - treatment with tomudex 179, (Short report) 961
 - combined chemotherapy-radiotherapy
 - as a treatment for patients with localized low-grade lymphoma 157
 - combined modality therapy
 - as a treatment for patients with bulky or advanced Hodgkin's disease (Review) S4: 105
 - as a treatment for patients with Hodgkin's disease (Special article) 555
 - as a treatment for patients with non-Hodgkin's disease 925
 - as a treatment for patients with stage I, II MALT lymphoma and mantle cell lymphoma (Letter to the editor) 211
 - complete remission
 - after 2-CdA therapy 373
 - in patients with CLL 373
 - continuous infusion
 - for patients with advanced colorectal cancer 581
 - of 5-HU plus leucovorin 581
 - cord blood
 - as an alternative source of haemopoietic stem cells (Review) S2: 47
 - in peripheral blood progenitor cell transplantation (Introduction) S2: 1
 - corticosteroids
 - in granulosa cell tumour of the ovary (Clinical case) 521
 - counseling
 - of genetic testing (Special article) 891
 - CPT-11
 - dosage schedules 837
 - cromoglycate
 - docetaxel rechallenge (Editorial) 104
 - current strategies
 - in treatment of Hodgkin's disease (Review) S4: 109
 - cyclin D1
 - identification of molecular alterators (Editorial) 222
 - involvement in hairy cell leukemia 251
 - clinical significance of 695
 - cyclin-dependent kinase
 - fundamental research (Commentary) 343
 - cyclin-dependent kinase inhibitors
 - fundamental research (Commentary) 343
 - cyclins
 - fundamental research (Commentary) 343
 - cyclophosphamide
 - delayed emesis inducement 71
 - cytogenetics
 - in Hodgkin's disease (Review) S4: 49
 - cytokines
 - haemopoietic stem cells (Review) S2: 47
 - in peripheral blood progenitor cell transplantation (Introduction) S2: 1
 - production in adult mice (Review) S2: 15
 - production in patients with AML 397
 - purging of peripheral blood progenitor cells (Review) S2: 11
 - treatment with interleukin-10 397
 - cytolytic T-lymphocytes
 - perspectives for peptide-based vaccines (Review) 339
 - recognition of tumour-associated antigens (Review) 339
- D**
- DAM486IL-2
 - clinical use in Hodgkin's disease (Review) S4: 135

- delayed emesis
 - caused by emetogenic chemotherapy 71
 - cisplatin-induced 945
 - oral dexamethasone in prophylaxis 71
- delayed nausea
 - cisplatin-induced 945
- detoxification
 - role of the LRP protein 625
- dexamethasone
 - compared to placebos and ondansetron 945
 - for control of cisplatin-induced delayed emesis 945
 - prevention of hypersensitive reactions to paclitaxel (Letter to the editor) 978
 - emetogenic chemotherapy 71
- developmental therapeutics
 - in the treatment of patients with germ-cell tumours (Review) 997
- diarrhoea
 - comparing drugs for the prevention of 587
- disseminating disease
 - expression of tyrosinase 297
 - reverse transcriptase-polymerase chain reaction 297
 - through peripheral blood 297
- DNA primase
 - in cancer therapy (Review) 659
- DNA topoisomerase I inhibitor
 - in CPT-11 837
- docetaxel
 - efficacy and safety as a treatment for patients with advanced breast cancer 165
 - rechallenge with cromoglycate (Editorial) 104
- dosage schedules
 - of CPT-11 837
- dose
 - phase I trials (Commentary) 567
- dose escalation
 - current clinical trials in Hodgkin's disease (Review) S4: 109
 - of high-dose CDE with G-CSF for poor-risk non-Hodgkin's lymphoma 1037
 - phase I trials (Commentary) 567
- dose-finding
 - study in chemotherapy 505
 - of tropisetron 505
- dose intensity
 - in chemotherapy for patients with adult solid tumours (Review) S2: 23
 - in chemotherapy for patients with breast cancer 35, (Review) S2: 31
 - in primary chemotherapy for patients with ovarian carcinoma 705
 - in therapy for patients with colorectal cancer 41
 - peripheral blood progenitor cells (Review) S2: 11
- dose-limiting toxicity
 - phase I trials (Commentary) 567
- dose-response
 - in patients with breast cancer (Review) S2: 31
 - relationship in patients with advanced Hodgkin's disease (Review) S4: 95
- doxorubicin
 - in advanced breast cancer 687
- drug therapy
 - and hematopoietic rescue 151
 - as a treatment for patients with Hodgkin's disease 151
- E
 - early breast cancer
 - treatment with adjuvant chemotherapy 239
 - treatment with tamoxifen 239
 - early stages
 - of Hodgkin's disease (Review) S4: 79, 85, 91
 - EBV-specific immunity
 - by EBV-induced modulation of cytokine expression pattern of HRS cells (Review) S4: 11
 - 8-chloroadenosine 3',5'-monophosphate (8-Cl-cAMP)
 - metabolism 291
 - pharmacokinetics 291
 - treatment for patients with breast cancer 291
 - tumour disposition 291
 - elderly patients
 - age specific differences 677
 - diagnostics and treatment 677
 - effects of granulocyte colony-stimulating factor administration (Short report) 966
 - treatment with a pirarubicin-combination chemotherapy regimen (Short report) 966
 - emesis
 - cisplatin induced 277
 - comparing drugs for the prevention of nausea 587
 - in patients undergoing fractionated radiotherapy 587
 - optimum therapy 277
 - end results
 - of the treatment of patients with Hodgkin's disease (Special article) 555
 - endocrine pancreatic tumours
 - treatment with chemotherapy (Review) 453
 - endocrine therapy
 - as a treatment of patients with breast cancer (Short report) 99
 - endometrial cancer
 - treatment with paclitaxel (Short report) 861
 - endothelium
 - influence of 5-fluorouracil and methotrexate 731
 - epidemiology
 - importance (Editorial) 439
 - of cancer 497
 - of EBV and Hodgkin's lymphoma (Review) S4: 5
 - epidoxorubicin
 - distribution in mice (Rapid publication) 801
 - epithelial neoplasms
 - the role of chemotherapy (Review) S2: 23
 - Epstein-Barr virus (EBV)
 - after solid organ transplantation 265
 - and Hodgkin's disease 265, (Symposium article) S4: 45
 - epidemiology and Hodgkin's lymphoma (Review) S4: 5
 - its role in the pathogenesis of Hodgkin's disease (Review) S4: 11
 - Erwinia chrysanthemi
 - exposures to children with acute lymphoblastic leukemia 725
 - esophagogastric junction area
 - advanced adenocarcinoma (Short report) 533
 - treatment with 5-FU and folinic acid (Short report) 533
 - esophagus
 - advanced adenocarcinoma (Short report) 533

- treatment with 5-FU and folinic acid (Short report) 533
- estrogen receptors
in breast cancer cells 391
- estrogenic recruitment
in metastatic breast cancer 487
- ethics
of euthanasia 907
- European perspective
on clinical benefits (Editorial) 333
- euthanasia
ethics of 907
physician-assisted (Editorial) 879
versus palliative care (Letter to the editor) 645, (Editorial) 879
- ex vivo expansion
of stem cells in mice (Review) S2: 15
- ex vivo purging
of peripheral blood progenitor cells (Review) S2: 11
- extradonal lymphomas
state-of-the-art (Commentary) 787
treatment (Commentary) 787
- evaluation criteria
for response rates in advanced colorectal cancer (Arena) 901
- F**
- FA administration
neurotoxicity (Letter to the editor) 213
- fadrozole
versus tamoxifen in patients with advanced breast cancer 471
versus tamoxifen in patients with metastatic breast cancer 465
- fallopian tube carcinoma
survival analysis 271
- fibrinogen
interaction between HRT and tamoxifen 671
- FICTION**
and the monoclonality of Hodgkin and Reed-Sternberg cells (Review) S4: 49
- financial costs
of intravenous infusion with 5-fluorouracil 307
- FISH**
molecular cytogenetics in Hodgkin's disease (Review) S4: 49
- fixed effects
in childhood leukemia clinical research (Arena) 1009
- 5-fluorouracil
and methotrexate on vascular endothelium 731
as a treatment for patients with advanced colorectal cancer 581
as a treatment for patients with advanced pancreatic adenocarcinoma 173
as a treatment for patients with biliary tract cancer (Letter to the editor) 644
as a treatment for patients with breast cancer (Short report) 409, (Editorial) 771
as a treatment for patients with metastatic colorectal carcinoma 575
biologically modulated by folinic acid (Letter to the editor) 644
comparison of results to tissue dry levels with or without interferon α (Short report) 533
folinic acid association 283
in advanced adenocarcinoma (Short report) 533
in cancer chemotherapy 283
in colorectal cancer 41, (Editorial) 551, 581
in combination therapy in metastatic carcinoid and malignant endocrine pancreatic tumours (Short report) 208
in combination with leucovorin 581
infusional (Short report) 55, 409, 581, (Editorial) 771, 807
measurement of plasma 47
neurotoxicity (Letter to the editor) 213
phase I/II study 55, 581
radiotherapy 511
- 5-fluorouracil infusion
as a treatment for patients with advanced breast cancer 807
- 5-HT₃ receptor antagonist
compared with placebos and dexamethasone 945
for the control of cisplatin-induced delayed emesis 945
- floxuridine
in combination with recombinant α 2b-interferon 601
treatment of patients with metastatic renal cell carcinoma 601
- fludarabine
as a treatment for patients with LCC 373
in therapy of low-grade follicular lymphoma (Review) S6: 41
long term survival 373
- folinic acid
as a treatment for patients with advanced adenocarcinoma of the esophagus (Short report) 533
cancer chemotherapy 283
5-fluorouracil association 283
in combination with 5-FU (Short report) 533
phase I/II study 55
- follicular lymphoma
histological transformation (Clinical case) 849
stage I 713
2-CDA therapy (Rapid publication) 793
wait-and-see policy 713
- follicular small cleaved cell lymphoma
treatment with combined chemotherapy-radiotherapy 157
- fractionated radiotherapy
prevention of nausea and vomiting in patients 586
- future perspectives
for the treatment of Hodgkin's disease (Symposium article) S4: 127
- G**
- G-CSF
in elderly patients (Short report) 966
in patients with advanced non-small lung cancer and malignant melanoma (Short report) 1080
in patients with HIV-related non-Hodgkin's lymphoma 1029
in patients with poor-risk non-Hodgkin's lymphoma 1037
- gemcitabine
as a treatment for patients with pancreatic cancer (Editorial) 335, (Rapid publication) 347
phase II trial (Rapid publication) 347
- gene rearrangement
in the peripheral blood of patients with diffuse large B-cell lymphomas 1023
- gene therapy
as a new therapy for cancer (Special article) 449
expanding cord blood after allogeneic transplantation (Review) S2: 47
for patients with metastatic renal cell cancer (Review) 887
in peripheral blood progenitor cell transplantation (Introduction) S2: 1

- the challenge for the future (Review) S2: 53
- gene transfer
- in mice and man (Review) S2: 53
- genetic testing
- prevention of hereditary nonpolyposis colorectal cancer (Special article) 891
- germ cell neoplasms
- the role of chemotherapy (Review) S2: 23
- germ-cell tumours
- carboplatin in combination chemotherapy (Editorial) 989
- high-dose chemotherapy (Review) 997
- GM-CSF
- in patients with AML 397
- in patients with metastatic breast cancer 35
- treatment with interleukin-10 397
- gonadal dysfunction after chemotherapy
- late effects in childhood Hodgkin's lymphoma (Review) S4: 67
- graft versus host disease
- allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
- in chronic myelogenous leukaemia (Review) S2: 19
- granisetron
- in emetogenic chemotherapy 71
- granulocytic sarcoma
- isolated (Letter to the editor) 424
- granulocyte colony stimulating factor
- in allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
- granulocyte growth factors
- in adult solid tumours (Review) S2: 23
- in haematopoietic stem cells (Review) S2: 5
- in progenitors (Introduction) S2: 1
- in stem cells of adult mice (Review) S2: 15
- granulosa cell tumour
- of the ovary (Clinical case) 521
- growth factors
- after treatment with pentosan 939
- H**
- haemoptysis
- in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
- haematopoiesis
- transplantation of peripheral blood progenitor cells (Review) S2: 41
- haematopoietic stem cells
- cord blood as an alternative source (Review) S2: 47
- repopulating ability in mice (Review) S2: 15
- study of cells in patients (Review) S2: 5
- haematopoietic stem cell transplantation
- and drug therapy 151
- in Hodgkin's disease patients 151
- hairy cell leukemia (HCL)
- involvement of the CCND1 gene 251
- head and neck cancer
- treatment with chemotherapy 15
- head and neck neoplasms
- re-irradiation with concomitant chemotherapy 913
- heart transplantation
- pretransplant malignancy in candidates and posttransplant malignancy in recipients 1059
- Helicobacter pylori*
- association with MALT lymphoma (Commentary) 787
- hematological recovery
- prognostic factors for autograft patients 719
- heparan sulfate
- as a treatment for patients with advanced malignancies 939
- heparinoid
- pentosan 939
- hepatic artery infusion
- in liver metastases of colorectal cancer (Short report) 317
- with interleukin-2 (Short report) 317
- hereditary colon cancer
- prevention by genetic testing (Special article) 891
- high-dose chemotherapy
- for Hodgkin's lymphoma (Symposium article) S4: 131
- for patients with poor-risk non-Hodgkin's lymphoma 1037
- in germ-cell tumours (Review) 997
- high-dose single agent chemotherapy
- in Hodgkin's disease (Review) S4: 109
- high-dose VP-16
- in patients with bone marrow transplantation 83
- high performance liquid chromatography
- measurement of plasma 5-FU 47
- treatment of patients with colorectal cancer 47
- histopathology
- of lymphocyte predominant Hodgkin's disease (Symposium article) S4: 61
- historical control studies
- compared with randomized trials 355
- of patients with esophageal carcinoma 355
- HIV
- hematopoietic colony-stimulating factors (Arena) 233
- related with non-Hodgkin's lymphoma's (Arena) 233
- Hodgkin's disease
- analysis of tumor cells (Symposium article) S4: 45
- autologous hematopoietic rescue 151
- brief chemotherapy and adjuvant radiotherapy (Review) S4: 105
- clinical trials (Symposium article) S4: 127
- complications by second cancers (Clinical case) 405
- current clinical trials (Review) S4: 109
- current strategies (Review) S4: 91
- cytogenetics and molecular cytogenetics (Review) S4: 49
- development of immunotoxins for potential use (Review) S4: 135
- early high dose chemotherapy (Symposium article) S4: 131
- early stage (Editorial) 115, (Review) 85, 91
- evidence of the Epstein-Barr virus 265
- following solid organ transplantation 265
- Ig rearrangements in isolated Reed-Sternberg cells (Review) S4: 31
- increased risks in females 257
- interactive signals in the pathobiology (Review) S4: 19
- late complications (Review) S4: 115
- long-term results of radiotherapy 145
- management of early stage (Review) S4: 79
- meningeal localization in a patient (Clinical case) 1071
- occurrence of cardiopulmonary sequelae 257
- patients with an incomplete response to front-line therapy 1043

- preliminary experience with paclitaxel (Short report) 1083
 present and future strategies of treatment in childhood (Review) S4: 73
 rationale for dose escalation of first line conventional chemotherapy (Review) S4: 95
 role of Epstein-Barr virus in the pathogenesis (Review) S4: 11
 role of radiation therapy and/or chemotherapy (Review) S4: 79
 role of radiation therapy in advanced disease (Review) S4: 99
 single cell analysis of Hodgkin/Reed-Sternberg cells (Review) S4: 27, 41
 single cell PCR for the analysis (Review) S4: 35
 treatment (Special article) 555
 treatment with bispecific antibodies (Review) S4: 143
 treatment with high-dose chemotherapy 151
- Hodgkin's lymphoma**
 epidemiology (Review) S4: 5
 overview of the Third International Symposium (Introduction) S4: 1
- hormonal replacement therapy**
 as a treatment for patients with a breast cancer history (Editorial) 655
 effect on serum cholesterol, bone mineral density and coagulation factors 671
 interaction with tamoxifen 671
- HUMARA gene assay**
 in single cell analysis of H/RS cells (Review) S4: 41
- hypnotics**
 discontinuation in terminal cancer patients (Short report) 855
- I**
- ifosfamide**
 as a treatment for patients with advanced ovarian cancer (Short report) 419
 as a treatment for patients with malignant melanoma (Short report) 1080
 as a treatment for patients with non-small-cell lung cancer (Short report) 311, 314, 747, (Short report) 637, (Short report) 1080
 in combination with methylene-blue (Letter to the editor) 643
 in salvage therapy (Short report) 419
 phase I study (Short report) 311, 314
 phase II study (Short report) 637, (Short report) 1080
 oral versus intravenous (Short report) 637
- Ig gene rearrangements**
 in Hodgkin/Reed-Sternberg cells (Review) S4: 27
- imaging procedures**
 in Hodgkin's disease (Review) S4: 55
- immunogenotype**
 in lymphocytic leukemia (Clinical case) 953
- immunoglobulin gene rearrangement**
 by PCR in single cell analysis of H/RS cells S4: 41
- immunoglobulin heavy chain rearrangements**
 in HRS cells (Review) S4: 35
- immunoglobulin rearrangement**
 in isolated Reed-Sternberg cells (Review) S4: 31
- immunohistochemistry**
 detection of MRP expression 75
 in hairy cell leukemia 251
 involvement of the CCND1 gene 251
 involvement of the LRP gene 625
- immunophenotype**
 in lymphocytic leukemia (Clinical case) 953
- immunoassay**
 new diagnostic procedure in Hodgkin's disease (Review) S4: 55
- immunotherapy**
 of Hodgkin's disease (Review) S4: 143
 of metastatic renal cell cancer (Review) 887
 monitoring of cancer vaccines (Commentary) 667
- immunotoxin**
 development for potential clinical use in Hodgkin's disease (Review) S4: 135
- in vitro expansion**
 of haemopoietic stem cells (Review) S2: 47
- in vivo purging**
 of peripheral blood progenitor cells (Review) S2: 11
- incidence**
 and mortality 497
- Indiana University classification**
 randomized trial for patients with good-risk metastatic non-seminomatous germ cell tumours 1015
- indoloquinone EO9**
 in non-small-cell lung cancer (Short report) 529
- induction failure**
 in patients with lymphoma 1043
- inflammatory disease**
 dose-response effect (Review) S2: 31
- infusional**
 CMF (Short report) 409
- inter-abdominal abscess**
 complications for chemotherapy (Letter to the editor) 536
- interaction**
 between paclitaxel and EpiDx (Rapid publication) 801
- interferon**
 as a treatment for patients with colorectal cancer patients 47
 as a treatment for patients with metastatic renal cell carcinoma 601
 in combination with floxuridine 601
- interferon- α**
 as a treatment for patients with chronic myelogenous leukaemia (Review) S2: 19
 as a treatment for patients with metastatic melanoma 827
 in combination with biotherapy 827
- intergroup trials**
 prospective meta-analysis strategy (Arena) 1005
- interleukin-2**
 as a treatment for out-patients with metastatic renal cell carcinoma (Short report) 525
 as a treatment for patients with colorectal cancer (Short report) 317
 as a treatment for patients with metastatic melanoma 827
 prolonged continuous hepatic artery infusion (Short report) 317
 phase I study (Short report) 317
 peripheral nerve entrapment (Letter to the editor) 535
- interleukin-10**
 for patients with AML 397
 inhibition of cytokine production 397
- interleukins**
 as a treatment for patients with metastatic renal cell cancer (Review) 887
- intermediate- to high-grade non-Hodgkin's lymphomas**
 combined modality treatment 919
- investigational agents**
 in patients with refractory malignancies 491
- irinotecan**
 dosage schedules 837

- inlet cell
 combination therapy with interferon- α -2a and 5-FU (Short report) 208
- isolated granulocytic sarcoma
 of the breast (Letter to the editor) 424
- L**
- L-asparaginase
 exposure to Erwinia 725
- L-asparagine depletion
 in children with acute lymphoblastic leukemia 725
- laboratory
 research of ovarian cancer 9
- large cell lymphoma
 clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood 1023
- late complications
 after Hodgkin's disease (Review) S4: 115
- late effects of chemotherapy
 in childhood Hodgkin's lymphoma (Review) S4: 67
- leptomeningitis
 carcinomatous meningitis (Review) 773
- letrozole
 as a treatment for patients with breast cancer (Short report) 99
- leucovorin
 as a treatment for patients with advanced colorectal cancer 581
 as a treatment for patients with advanced pancreatic adenocarcinoma 173
 in combination with 5-FU 581
- leukaemia
 complicating Hodgkin's disease (Clinical case) 405
- levamisole
 role in treatment of patients with colorectal cancer 41
- ligands
 TNF superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19
- limited stages
 causing complications 713
- LMP1
 pathogenesis of Hodgkin's disease (Review) S4: 11
- localized
 stage NHL 919
- locally advanced breast cancer
 efficacy and safety of docetaxel 165
- low-dose continuous
 intravenous infusion of 5-fluorouracil 807
- low-grade follicular lymphoma
 purine nucleoside therapy (Review) S6: 41
- lung cancer
 carcinomatous meningitis (Review) 773
 expression of the LRP protein 625
 non-small-cell (Editorial) 119, (Short report) 311, 314
 phase I study (Short report) 311, 314
 radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy 139
 randomized phase II trials (Letter to the editor) 755
 role of surgery in small-cell (Clinical case) 303
 treatment with chemotherapy (Short report) 311, 314
- lung neoplasms
 the role of chemotherapy (Review) S2: 23
- lung resistance-related protein (LRP)
 expression in human lung cancer 625
 role in drug resistance 625
- lymphoma
 clonal analysis (Clinical case) 953
 evolution into lymphocytic leukemia (Clinical case) 953
 treatment with a pirarubicin-combination chemotherapy regimen (Short report) 966
 treatment with paclitaxel (Short report) 1083
- lymphopoiesis
 reconstruction after allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
- lymphocyte predominance Hodgkin's disease
 a workshop report (Symposium article) S4: 61
- M**
- magnetic resonance spectroscopy
 of colorectal cancer 47
- malignancy
 in recipients of cardiac transplantation 1059
- malignant glioma
 phase II study (Short report) 205
- MALT lymphoma
 combined modality therapy (Letter to the editor) 211
Helicobacter pylori (Commentary) 787
 purine analogs (Review) S6: 21
 state-of-the-art (Commentary) 787
- MALToma
 new classification (Review) S6: 3
- management
 of patients with tumour lysis syndrome (Clinical case) 631
- mantle cell lymphoma (MCL)
 classification and therapeutic implications (Review) S6: 35
 treatment with combined modality therapy (Letter to the editor) 211
- marginal-zone lymphomas
 purine analogs (Review) S6: 21
- marrow repopulation
 in mice (Review) S2: 15
- maspin
 reverse-transcriptase polymerase chain reaction of 619
 role in breast cancer 619
- matrix attachment regions
 in cancer therapy (Review) 659
- melanoma
 identification in peripheral blood 297
 treatment with biochemotherapy 827
- melphalan
 as a treatment for patients with ovarian cancer 65
- meningeal lymphoma
 in patients with Hodgkin's disease (Clinical case) 1071
- meta-analysis
 strategy in childhood leukemia clinical research (Arena) 1009
- metabolism
 in patients with breast cancer 291
 of 8-chloroadenosine 3',5'-monophosphate 291
- metastasis
 treatment with neoadjuvant chemotherapy (Short report) 864
- metastatic breast cancer

- treatment with chemotherapy 487
- clubbing, arthralgia and haemoptysis (Letter to the editor) 756
- detection of 619
- efficacy and safety of docetaxel 165
- maspin gene 619
- metastatic colorectal carcinoma
 - treatment with 5-fluorouracil plus α -interferon 575
- metastatic disease
 - dose intensification (Review) S2: 31
- metastatic liver disease
 - results of cancer treatment (Letter to the editor) 871
- metastatic renal cell carcinoma
 - treatment with floxuridine plus interferon α -2b-interferon 601
- metastatic spinal cord compression
 - in patients with small-cell lung cancer (Letter to the editor) 321
- methadone
 - as a treatment for patients with cancer pain 613
- methodology
 - phase I trials (Review) S61
- methotrexate
 - in gene therapy (Review) S2: 53
 - as a treatment for patients with solid tumours 59
- methylene-blue
 - in combination with ifosfamide (Letter to the editor) 643
- mice
 - repopulating ability (Review) S2: 15
- micromanipulation
 - of single Hodgkin/Reed-Sternberg cells (Review) S4: 27
- mitomycin-C
 - as a treatment for patients with biliary tract cancer (Letter to the editor) 644
- mitoxantrone
 - as a treatment for patients with adenoid cystic carcinomas (Short report) 867
 - as a treatment for patients with advanced ovarian cancer (Short report) 419
 - as a treatment for patients with breast cancer (Short report) 745
 - salvage therapy (Short report) 419
- molecular tumour markers
 - and clonality (Review) 121
- monitoring of cancer vaccines
 - immunotherapy (Commentary) 667
- monocytoid B-cell lymphomas
 - purine analogs (Review) S6: 21
- mortality
 - trends in cancer 497
- MRI (magnetic resonance imaging)
 - diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
- multicentric
 - osteosarcoma (Short report) 864
- multidrug resistance
 - in lung cancer 625
 - LRP protein 625
- multidrug resistance-associated protein (MRP)
 - expression in lung cancer 625
 - in NSCLC 75
 - relation with LRP 635
- multifocal leucoencephalopathy
 - treatment of patients with colon cancer (Short report) 412
- multiple myeloma
 - treatment with oral idarubicin and prednisone (Letter to the editor) 537
- N
- N-myc
 - treatment of patients with neuroblastoma 183
- nausea
 - induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy 505
 - comparing the effect of ondansetron plus dexamethasone and metoclopramide plus dexamethasone 277
- neo-adjuvant chemotherapy
 - versus radiotherapy in non-small-cell lung cancer 139
- nephrotoxicity
 - in chemotherapy for patients with non-small-cell lung cancer (Short report) 529
- neuroblastoma
 - diagnostic and prognostic value of biological markers 607
 - patterns of stages I, II and III 183
- neuroendocrine gastrointestinal tumours
 - management of the disease (Review) 453
- neuroendocrine tumours
 - combination therapy with interferon- α -2a and 5-fluorouracil (Short report) 208
- neurotoxicity
 - related to 5-fluorouracil and FA administration (Letter to the editor) 213
- node-negative breast cancer
 - adjuvant treatment 481
- non-cisplatin-containing regimen
 - as a treatment for patients with non-small-cell lung cancer 821
- non-Hodgkin's lymphoma
 - activity of single agent vinorelbine (Short report) 970
 - classification and clinical course (Review) S6: 13
 - hematopoietic colony-stimulating factors (Arena) 233
 - HIV-related (Arena) 233
 - intensive therapy and autotransplant 1043
 - MALT lymphoma's (Commentary) 787
 - new classification (Review) S6: 3
 - new prognostic factors (Editorial)
 - state-of-the-art (Commentary) 787
 - therapy in HIV-related diseases 1029
 - treatment with combined modality therapy 825
 - treatment with high-dose CDE with G-CSF without stem-cell support 1037
 - use of new agents (Editorial) 767
- nonmalignant complications
 - after Hodgkin's disease (Review) S4: 115
- non-small-cell lung cancer
 - expression of MRP 75
 - more power to trials (Editorial) 119
 - phase I study (Short report) 311, 314
 - phase II study (Short report) 747, (Short report) 637, 821
 - treatment with chemotherapy (Short report) 311, 314, (Short report) 637
 - treatment with ifosfamide/mesna 637
 - treatment with vinorelbine and vindesine 815
 - VIP and VIP-16 combination chemotherapies 517
- nuchal liposarcoma

cell transplantation (Letter to the editor) 871
 inoperable relapse (Letter to the editor) 871

nuclear matrix

as a target for cancer therapy (Review) 659

nucleoside analogue

long-term survival 373

as a therapy for patients with CLL 373

O

octreoscan

localizing neuroendocrine gastrointestinal tumours (Review) 453

OEPA

used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67

oesophageal neoplasms

treatment with chemotherapy 355

onapristone

antiproliferative potency 391

as a treatment for patients with breast cancer 391

stimulation of TGF-beta 391

ondansetron

as a treatment for cisplatin-induced emesis 277, 945

as a treatment for patients undergoing fractionated radiotherapy 587

compared with metoclopramide dexamethasone plus lorazepam 277

compared with placebos and dexamethasone 945

preventing nausea and vomiting 587, 945

OPA

used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67

OPPA

used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67

oral idarubicin

as a treatment for patients with advanced multiple myeloma (Letter to the editor) 537

organ transplantation

evidence of Epstein-Barr virus 265

as a treatment for patients with Hodgkin's disease 265

osteosarcoma

synchronous multifocal (Short report) 864

treatment with neoadjuvant chemotherapy (Short report) 864

out-patient

with metastatic renal cell carcinoma (Short report) 525

ovarian cancer

CA 125 levels 361

challenges for the future (Special article) 9

paclitaxel/cisplatin as initial therapy (Short report) 1077

progression 361

salvage therapy (Short report) 419

treatment with ifosfamide and mitoxantrone (Short report) 419

treatment with surgery, short-course chemotherapy and whole abdominal radiation 65

oxaliplatin

phase II study (Short report) 95

single agent activity in advanced ovarian cancer 1065

P

p53

in patients with node-positive breast carcinoma 695

paclitaxel

as a treatment for patients with advanced breast cancer 687, (Short report) 857

as a treatment for patients with advanced endometrial cancer (Short report) 861

as a treatment for patients with advanced ovarian cancer (Short report) 1077

as a treatment for patients with germ-cell tumours (Review) 997

as a treatment for patients with Hodgkin's disease (Letter to the editor) 423

as a treatment for patients with non-Hodgkin's lymphoma (Letter to the editor) 423

as a treatment for patients with non-small-cell lung cancer (Short report) 311, 314

as a treatment for patients with relapsed and refractory Hodgkin's disease (Short report) 1083

as a treatment for patients with solid tumours 59

inducing changes in epidoxorubicin (Rapid publication) 801

inducing radiation recall dermatitis (Letter to the editor) 755

phase I study (Short report) 311, 314

phase II study 31, (Short report) 857, (Short report) 861

prevention of hypersensitivity (Letter to the editor) 978

palliation

in patients with advanced colorectal cancer (Short report) 961

use of chemotherapy 593

palliative care

and cancer patients (Arena) 135

versus euthanasia (Letter to the editor) 645, 907

palliative therapy

for patients with breast cancer 807

pancreatic cancer

improvement of quality of life 593

phase II trial (Rapid publication) 347

prolongement of survival 593

treatment with gemcitabine (Editorial) 335, (Rapid publication) 347

use of chemotherapy 593

paragranuloma

classification of lymphocyte predominant Hodgkin's disease cases (Symposium article) S4: 61

paraplegia

in patients with small-cell lung cancer (Letter to the editor) 321

pathogenesis

of Hodgkin's disease (Review) S4: 19

patient-controlled analgesia

use of methadone in cancer pain 613

patterns of care

of elderly cancer patients 677

patterns of relapse

effects of prednisone combined with CMF 245

in patients with breast cancer 245

pediatric oncology

clinical research in childhood ALL (Arena) 1005

pentosan

as a treatment for patients with advanced malignancies 939

peripheral blood

autotransplant of progenitor cells 719

cell mobilisation following G-CSF 1051

- peripheral blood progenitor cells (Introduction) S2: 1
 in adult solid tumours other than breast cancer (Review) S2: 23
 in chronic myelogenous leukaemia (Review) S2: 19
 purging of (Review) S2: 11
- peripheral blood stem cells
 dose intensification in patients with breast cancer (Review) S2: 31
 gene therapy (Review) S2: 53
 mobilisation and collection (Review) S2: 9
 repopulating ability in mice (Review) S2: 15
- peripheral nerve entrapment
 high-dose interleukin-2 therapy (Letter to the editor) 535
- pharmacokinetics
 application schedules in patients with bone marrow transplantation 83
 anthracyclines (Rapid publication) 801
 8-chloroadenosine 3',5'-monophosphate 291
 in breast cancer patients 291
- pharmacomodulation
 5-fluorouracil-folinic acid association 283
- phase I trials
 of methotrexate and paclitaxel with and without G-CSF 59
 methodology (Review) 561
 of bi-weekly paclitaxel/cisplatin as therapy for advanced ovarian cancer (Short report) 1077
 of pentosan 939
- phase I/II trials
 of 5-FU plus high-dose folinic acid 55
- phase II trials
 of a closely spaced ifosfamide-cisplatin schedule with the addition of G-CSF (Short report) 1080
 of CAP regimen (Short report) 640
 of 5-FU in combination with leucovorin 581
 of floxuridine plus recombinant α -2b-interferon 601
 of mitoxantrone (Short report) 867
 of mytomycin-C in combination with 5-fluorouracil (Letter to the editor) 644
 of oral ifosfamide versus intravenous ifosfamide (Short report) 637
 of oxaliplatin (Short report) 95
 of paclitaxel 31
 of 13-cis retinoic acid plus interferon- α (Letter to the editor) 539
 of topotecan (Short report) 205
- Philadelphia negative cells
 in chronic myelogenous leukaemia (Review) S2: 19
- platinum induction
 as induction chemotherapy for patients with small-cell lung cancer 365
- polymerase chain reaction (PCR)
 detection of peripheral blood bcl-2 (MBR)/JH rearrangement 1023
 detecting the nature of HRS cells (Review) S4: 31
 for analysis of Hodgkin's disease (Review) S4: 35
- polymers
 in cancer chemotherapy (Special article) 445
- positron emission tomography (PET)
 as a method to diagnose residual disease (Short report) 416
 as a method to diagnose tumour emboli (Short report) 416
 in choriocarcinoma (Short report) 416
 new diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
- postmenopausal
 patients with metastatic breast cancer 465
- prednisone
 as a treatment for advanced multiple myeloma (Letter to the editor) 537
 combined with CMF 245
 development of bone metastases (Letter to the editor) 643
 effects of treatment in patients with breast cancer 245
 effects on patterns of relapse 245
- prevention
 of hereditary nonpolyposis colorectal cancer (Special article) 891
 previously untreated stages IIIB or IV non-small cell lung cancer
 treatment with vinorelbine and vindesine 815
- primary surgery
 as a treatment for patients with small-cell lung cancer 303
- prochlorperazine
 as antiemetic (Editorial) 103
- progenitor assays
 standards for PBSC mobilisation and collection (Review) S2: 9
- progenitor thresholds
 standards for PBSC mobilisation and collection (Review) S2: 9
- progesterone receptors
 in breast cancer cells 391
 stimulation of TGF-beta 391
- prognosis
 anti-cancer serological response (Review) 227
 by biological markers 607
 for patients with follicular lymphoma (Clinical case) 849
 for patients with lymphocyte predominant Hodgkin's disease (Symposium article) S4: 61
 of cyclin D1 in patients with node-positive breast carcinoma 699
 of neuroblastoma 607
- prognostic factors
 associated with hematopoietic recovery in autograft patients 719
 developed from clinical trials of early stage Hodgkin's disease (Review) S4: 80
 expression of Bax in relation to Bcl-2 (Rapid publication) 129
 in patients with breast cancer (Rapid publication) 129
 in patients with diffuse large cell non-Hodgkin's lymphoma (Editorial) 993
 in patients with early stage Hodgkin's disease (Review) S4: 79, 91
 in patients with germ-cell tumours (Review) 997
 in patients with good-risk metastatic non-seminomatous germ cell tumours 1015
 of t(14;18) in the blood of patients with DLCL 1023
 using early high dose chemotherapy on patients with Hodgkin's disease (Symposium article) S4: 131
- progression
 according to CA 125 361
 of ovarian carcinoma 361
- prospective meta-analysis
 strategy for inter-group collaboration (Arena) 1005
- prostacyclin
 release by the bovine endothelial cells 731
- psychology
 patient perceptions of the effects of chemotherapy 189
- psycho-oncology
 palliative and supportive care (Arena) 135
- pulmonary sequelae
 after treatment for Hodgkin's disease 257
 increased risks in females 257
- pulmonary toxicity

after treatment with high-dose vinorelbine and mitomycin C (Short report) 973

purging

of peripheral blood progenitor cell transplantation (Introduction) S2: 1

purine analogs

in chronic lymphocytic leukemia and Waldenström's macroglobulinemia (Review) S6: 27

in mantle-cell lymphoma (Review) S6: 35

in marginal-zone lymphomas (Review) S6: 21

therapy of low-grade follicular lymphoma (Review) S6: 41

therapy of low-grade non-Hodgkin's lymphomas (Review) S6: 13

Q

quality of life

CARES-SF as an instrument in clinical trials 381

improvement by treatment with FU-LDCI 807

of patients with breast cancer 807

of patients with Hodgkin's disease (Review) S4: 115

of patients with pancreas cancer (Rapid publication) 347

prevention of nausea and vomiting 587

R

radiation

recall dermatitis (Letter to the editor) 755

in Hodgkin's disease 257

increased risks in females 257

paclitaxel-induced (Letter to the editor) 755

pulmonary sequelae 257

therapy for patients with anaplastic carcinoma of the thyroid (Clinical case) 739

therapy for patients with bulky or advanced Hodgkin's disease (Review) S4: 105

radioprotection

therapy for patients with advanced Hodgkin's disease (Review) S4: 99

short-term repopulating ability in mice (Review) S2: 15

radiotherapy

as a treatment for patients with Hodgkin's disease (Special article) 555, (Review) S4: 109, (Clinical case) 1071

as a treatment for patients with locally advanced carcinoma of the cervix 511

clinical stage I and II Hodgkin's disease 145

combined with chemotherapy in NHL 919

of low-grade non-Hodgkin's lymphomas (Review) S6: 13

role in management of early stage Hodgkin's disease S4: 79

setrons (Editorial) 553

versus radiotherapy preceded by high-dose chemotherapy in non-small-cell lung cancer 139

random effects

in meta-analysis in childhood leukemia clinical research (Arena) 1009

randomization

in meta-analysis in childhood leukemia clinical research (Arena) 1009

randomized

phase II trial in lung cancer (Letter to the editor) 755

phase II trial in non-small-cell lung cancer 815

randomized clinical trials

for patients with advanced Hodgkin's disease (Review) S4: 95

randomized controlled trials

compared to historical control studies 355

for patients with esophageal carcinoma 355

randomized trial

in childhood ALL: the prospective meta-analysis strategy for inter-group collaboration (Arena) 1005

investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma 705

investigating chemotherapy for the improvement of survival and quality of life 593

of PEB versus CEB 1015

REAL classification

of mantle-cell lymphoma S6: 35

receptors

TNF superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19

recurrence

of head and neck neoplasms 913

of neuroblastomas 183

Reed-Sternberg cell

single cell analysis (Review) S4: 27, 41

refractory lymphoma

intensive therapy and autotransplant 1043

registry

of mortality 497

re-irradiation

of recurrent head and neck cancer 913

relapse

in patients with ovarian cancer 361

remission

after 2-CdA therapy 373

in patients with CLL 373

renal cell carcinoma

treatment of patients with floxuridine plus recombinant $\alpha 2b$ -interferon 601

treatment of patients with interferons and interleukin-2 (Review) 887

treatment of patients with subcutaneous recombinant interleukin-2 (Short report) 525

renal failure

occurrence in patients with tumour lysis syndrome (Clinical case) 631

repeated treatments

with cisplatin induced emesis 277

residual disease

diagnosis of (Short report) 416

in choriocarcinoma (Short report) 416

resistance mechanisms

in gene therapy (Review) S2: 53

response

to dose escalation schemes (Commentary) 567

phase I trials (Commentary) 567

response rate

effect of radiotherapy preceded by chemotherapy versus radiotherapy 139

of patients with locally advanced non-small-cell lung cancer 139

retroviral vectors

gene therapy (Review) S2: 53

Review

allogeneic transplantation of peripheral blood progenitor cells S2: 41

carcinomatous meningitis in solid tumour 773

chemotherapy for squamous cell carcinoma of head and neck 15

- development of immunotoxins for potential clinical use in Hodgkin's disease S4: 135
- dose intensification and breast cancer: Current results and future perspectives S2: 31
- gene therapy – the challenge for the future S2: 53
- immunotherapy of metastatic renal cell cancer 887
- mobilization of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia S2: 19
- neuroendocrine gastrointestinal tumours 453
- new classification of low-grade lymphoma S6: 3
- 1975–1995 revised anti-cancer serological response 227
- nuclear matrix as a target for cancer therapy 659
- peripheral blood progenitor cell transplantation (Introduction) S2: 1
- phase I trial design 561
- recognition of tumour-associated antigens by T-lymphocytes 339
- role of high dose chemotherapy in adult solid tumours other than breast cancer S2: 23
- standards for PBSC mobilisation and collection S2: 9
- study of haemopoietic stem cells in patients S2: 5
- tumour heterogeneity and clonality 121
- RFTS-SMPT-dgA**
for potential use in Hodgkin's disease (Review) S4: 135
- Rhodamine 123**
purification of stem cells (Review) S2: 15
- risk-factor**
for patients with neuroblastoma 183
- RNA**
CCND1 gene 251
and hairy cell leukemia 251
- RNase protection assay**
in treatment of NSCLC 75
- Rosai-Dorfman Syndrome**
transformation into high-grade lymphoma (Letter to the editor) 977
- RT-PCR**
for identification of breast cancer cells 619
for identification of melanoma cells in peripheral blood 297
- S**
- salvage therapy**
in heavily pretreated advanced epithelial ovarian cancer 1065
in pretreated non-Hodgkin's lymphomas (Short report) 970
- screening**
by biological markers 607
of patients with neuroblastoma 183, 607
- second cancers**
in Hodgkin's disease (Clinical case) 405
leukemia (Clinical case) 405
- second-look surgery**
of ovarian cancer 65
- second malignancies**
effects of adjuvant chemotherapy 239
treatment with tamoxifen 239
- secondary cancers**
late complications after Hodgkin's disease (Review) S4: 115
- secondary neoplasm**
effects of adjuvant prednisone combined with CMF 245
in patients with breast cancer 245
- serological response**
biological and significance and clinical implications (Review) 227
- serum bFGF**
in advanced colorectal cancer 843
- serum VEGF**
in advanced colorectal cancer 843
- setrons**
radiotherapy (Editorial) 553
- SHML**
transformation into high-grade lymphoma (Short report) 977
- side effects**
of cancer chemotherapy 189
- single cell analysis**
of Reed-Sternberg cells (Review) S4: 31
- single cell isolation**
in the analysis of Hodgkin's disease (Review) S4: 35
- single cell PCR**
analysis of Hodgkin-Sternberg cells (Review) S4: 27
- small-cell lung cancer**
treatment with induction chemotherapy 365
paraplegia in patients (Letter to the editor) 321
purging of peripheral blood cells (Review) S2: 11
randomized trial 365
the role of surgery (Clinical case) 303
- solid tumours**
treatment with CPT-11 837
sequential use of methotrexate and paclitaxel 59
- solitary pulmonary nodule**
role of surgery 303
- somatostatin analogue**
in chemotherapy of neuroendocrine gastrointestinal tumours (Review) 459
- somatostatin receptor scintigraphy**
new diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
- splenectomy**
need for management of early stage Hodgkin's disease (Review) S4: 79
- stage I and II**
long-term results of radiotherapy 145
low-grade lymphoma 157
MALT lymphoma (Letter to the editor) 211
of Hodgkin's disease 145
of non-Hodgkin's lymphomas 825
- stage I and II low-grade lymphoma**
treatment with combined chemotherapy-radiotherapy 157
- stage IV non-small-cell lung cancer**
treatment with non-cisplatin-containing regimen 821
- staging**
small-cell lung cancer 303
- statistical models**
used in clinical trials of advanced Hodgkin's disease (Review) S4: 95
- stem cell assays**
in the study of haemopoietic stem cells in patients (Review) S2: 5
- stem cell transplantation**
allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
standards for PBSC mobilisation and collection (Review) S2: 9
- subcutaneous administration**
of rIL-2 in out-patients (Short report) 525
- sulfated polysaccharides**

- in patients with refractory malignancies 491
- supportive care
 - and cancer patients (Arena) 135
- surgery
 - as a treatment for patients with bone sarcomas (Short report) 864
- survival
 - subcutaneous rIL-2 programs (Short report) 525
 - of patients with advanced endometrial cancer (Short report) 861
 - of patients with head and neck cancer 913
- survival analysis
 - of primary carcinoma of the fallopian tube 271
- T**
- t(11;14)
 - involvement of the CCND1 gene 251
- t(14;18) chromosomal translocation
 - detecting cells (Rapid publication) 793
 - in patients with DLCL 1023
 - in patients with non-Hodgkin's lymphoma (Rapid publication) 793
- t-AML
 - occurrence following adjuvant chemotherapy for breast cancer (Short report) 745
- t-MDS
 - occurrence following adjuvant chemotherapy for breast cancer (Short report) 745
- tamoxifen
 - effect in healthy postmenopausal women 671
 - treatment for early breast cancer 239
 - versus fadrozole in patients with advanced breast cancer 465, 471
- taxoids
 - docetaxel 165
 - as a treatment for patients with advanced breast cancer 165
- taxol
 - preliminary experience with paclitaxel for treatment of Hodgkin's disease (Short report) 1083
- TCNU
 - in colorectal cancer (Letter to the editor) 211
- testicular cancer
 - treatment with paclitaxel (Rapid publication) 31
 - treatment with PEB *versus* CEB 1015
- TGF-beta
 - induction by an antiprogesterin 391
 - in human breast cancer cells 391
 - stimulation of growth due to onapristone 391
- therapy
 - anti-cancer serological response (Review) 227
 - for early stage Hodgkin's disease (Review) S4: 91
- Third International Symposium (Introduction) S4: 1
- thymidylate synthase inhibitor
 - antitumour activity in a range of solid tumours 179
- tomudex (Short report) 961
- thyroid cancer
 - anaplastic (Clinical case) 739
- time intensification
 - regimen in advanced stages of Hodgkin's disease (Review) S4: 109
- time trends
 - in cancer incidence and mortality 497
- TNF
 - receptor and ligand superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19
- Tomudex (ZD 1694)
 - antitumour activity in a range of solid tumours 179
 - as a treatment for patients with advanced colorectal cancer (Short report) 961
 - compared with 5-FU plus leucovorin 945
 - results of a randomised trial (Short report) 961
- topoisomerase II
 - activity in cancer drugs (Review) 659
 - chemotherapy for patients with breast cancer (Short report) 745
- topotecan
 - phase II study in patients with recurrent malignant glioma (Short report) 205
- total dose
 - in therapy for patients with colorectal cancer 41
- toxicity
 - of application schedules in patients with bone marrow transplantation 83
 - of cisplatin-based combination chemotherapy for patients with non-seminomatous germ cell tumours 1015
 - of early high-dose chemotherapy (Symposium article) S4: 131
 - of high-dose CDE with G-CSF in poor-risk non-Hodgkin's lymphoma 1037
 - of high-dose radiotherapy for patients with non-small-cell lung cancer 139
 - of high-dose radiotherapy preceded by chemotherapy for patients with non-small-cell lung cancer 139
 - of dose escalation schemes (Commentary) 567
 - risks for patients with bulky or advanced Hodgkin's disease (Review) S4: 105
- toxicology
 - phase I trials (Commentary) 567
 - responses to dose escalation schemes (Commentary) 567
- transformation
 - of indolent lymphoma (Clinical case) 849
- transition
 - from patients with neuroblastoma 183
- transplantation
 - of peripheral blood progenitor cells (Introduction) S2: 1, (Review) S2: 11, (Review) S2: 23
- treatment
 - of HIV-related non-Hodgkin's lymphomas (Arena) 233
 - of Hodgkin's disease in children (Review) S4: 67, 73
 - of patients with CLL 373
 - of patients with follicular lymphoma (Clinical case) 849
 - of patients with granulosa cell tumour of the ovary (Clinical case) 521
 - of patients with Hodgkin's disease (Review) S4: 109
 - options for early stage Hodgkin's disease (Review) S4: 91
 - usefulness of colony-stimulating factors (Arena) 233
 - with 2-CdA 373
- tropisetron
 - for the control of nausea and vomiting by chemotherapy 505
- tumour-enteric fistula formation (Letter to the editor) 536
- tumour antigens
 - perspectives for peptide-based vaccines (Review) 339
 - recognition by T-lymphocytes (Review) 339
- tumour-associated antigens (TAA)
 - anti-cancer serological response (Review) 227
- tumour biopsies

in patients with breast cancer 291
 of 8-chloroadenosine 3',5'-monophosphate 291

tumour cell phenotype
 pathogenesis of Hodgkin's disease (Review) S4: 11

tumour emboli
 diagnosis (Short report) 416
 in choriocarcinoma (Short report) 416

tumour growth
 kinetics in advanced Hodgkin's disease (Review) S4: 95
 role of bFGF and VEGF 843

tumour heterogeneity
 and clonality (Review) 121

tumour lysis syndrome
 review of literature (Clinical case) 631

tumour marker
 CA 125 361

tumour response
 in advanced colorectal cancer chemotherapy (Arena) 901

tumour vaccines
 as a treatment for patients with metastatic renal cell cancer (Review) 887

tumour volume
 criteria for response (Letter to the editor) 871

2-CdA-therapy
 as a treatment for patients with chronic lymphocytic leukemia 373
 as a treatment for patients with non-Hodgkin's lymphoma (Rapid publication) 793
 long-term survival 373

2-chlorodeoxyadenosine
 in therapy of chronic lymphocytic leukemia and Waldenström's macroglobulinemia (Review) S6: 27
 in therapy of low-grade follicular lymphoma (Review) S6: 41

2'-deoxycoformycin
 in therapy of chronic lymphocytic leukemia (Review) S6: 27
 in therapy of low-grade follicular lymphoma (Review) S6: 41

tyrosinase
 expression of 297
 as a method to identify melanoma cells in peripheral blood 297
 RT-PCR 297

V

vaccination
 anti-cancer serological response (Review) 227

vaccines
 used in cancer chemotherapy (Special article) 445

validation
 of CARTES-SF as a quality of life instrument 381

vinorelbine
 as a treatment of patients with non-small-cell lung cancer 815
 versus vinorelbine 815

vinorelbine
 acute pulmonary toxicity (Short report) 973
 as a treatment of patients with breast cancer (Short report) 857
 as a treatment of patients with non-small-cell lung cancer 815
 as a treatment of patients with advanced NSCLC (Short report) 747
 in pretreated non-Hodgkin's lymphomas (Short report) 970
 versus vinorelbine 815

visual analogue scales
 after discontinuation of hypnotics (Short report) 855

vomiting
 induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy 505

wait-and-see policy
 in stage I₀ follicular lymphoma 713

W

Waldenström's macroglobulinemia
 purine analogs (Review) S6: 27

whole abdominal radiation
 of ovarian cancer 65

Working Formulation
 morphological classification (Review) S6: 3
 REAL classification (Review) S6: 35

X

xenografts
 in mice 291

Index of authors Volume 7 (1996)

A

- Alders JG 511
 Aapro MS 553
 Aaronson NK 381
 Abad A 95
 Abigeres D 837
 Abrahamson AF 257
 Abu Rabin A 751
 Achterath W 55
 Airoma G 821
 Albertsson M 731
 Alexander E S4: 5
 Algeri R 747
 Alonso JL 643
 Amadori D 487
 Amadori S 933
 Ambros P 607
 Ambrosetti A 793
 Anagnostopoulos I S4: 61
 Andersen JS 347
 Anderson JR 151
 André T 173
 Andrei A 747
 Andrieu JM 525
 Andrizzi C 933
 Ang PT 71
 Angeletti CA 747
 Anselmo AP 1071
 Antoine E-C S2: 31
 Antón-Torres A 581
 Apolinario RM 625
 Aranda E 581
 Arbuck SG 567
 Ariad S 321
 Armand J-P 6, 837
 Armitage JO 151, S6: 1
 Armstrong AA S4: 5
 Arseniev L S2: 41
 Ascari E 537
 Ashley SE 671
 Athanasiadis I 15
 Atsumi R 491
 Audhuy B 575
 Audisio E 919
 Avenin D 173
 Avvisati G 1071
 Azli N 165
 Azzouzi K 173
- ### B
- Bacchi M 65, 471
 Bacci G 864
 Bachmann P 637
 Badwe RA 355
 Baert AL 871
 Baldini E 487, 747, 857
 Balzarotti M 970
 Bamberg M 755
 Bandieri E 619
 Bangerter M S4: 55
 Bapsy PP 424
 Barbarano L 537
 Barbareschi M 695
 Barbazza R 695
 Barbieri F 412
 Barneto I 581
 Barón JM 581
 Baroni CD 1071
 Barozzi P 619
 Barrington R 491
 Barth S S4: 135
 Batist G 1077
 Baumann I 1051
 Bayo R 719
 Becher R 55
 Bedikian A 827
 Benoy I 843
 Bensmaline MA 1065
 Benvenuto F S2: 19
 Beretta K 471
 Bergerat J-P 575
 Bergman B 365
 Bergonzi C 537
 Bernhard J 426
 Bernier J 541
 Bernstein Z 536
 Berthold F 183, 607
 Bertini M 919
 Bertino J S2: 53
 Bertoni F 1023
 Besa P 157
 Betticher DC 223, 793
 Bevilacqua P 695
 Bewermeier P 83
 Beyer J 31
 Bhanisali MS 355
 Bhatt RG 355
 Bianco AR 821
 Bierman PJ 151, 265
 Binder C 129
 Binder L 129
 Binder T S4: 55
 Biron P 996, 967
 Bisagni G 99
 Bishop MR 151
 Bitton R 939
 Blackburn N 208
 Blijham GH 879
 Bliss J 989
 Boaziz C 525
 Boccardo F 239
 Body JJ 643
 Boe J 257
 Boersma AWM 75
 Boesgaard M 687
 Bohlen H 397, S4: 45
 Bokemeyer C 31, 416, 755, 1015
 Bolhuis RLH 317
 Bonadonna G 221, 481, 970
 Bonazzi C 419
 Bonichon F 713
 Bonoldi E 695
 Boogaerts MA S2: 1
 Boonstra H 511
 Boracchi P 695
 Bordessoule D 966
 Borisch B 953
 Borsellino P 907
 Bosman FT 75
 Bosq J 925
 Bosshard G 1023
 Botto B 919
 Bougon N 165
 Bouleuc C 173
 Bovbjerg DH 977
 Boven E 35
 Boyle P 439
 Bradley B S2: 47
 Brandwein JM 1043
 Breu H 183
 Briccoli A 864
 Brienza S 95, 1065
 Brogginini M 343
 Brown TD 347
 Bruera E 855
 Brugger W 871, S2: 1, 11
 Brugnattelli S 537
 Brunelli C 907
 Brunetti I 601
 Buckley CH 705
 Bullorsky E 719
 Burchill S 297
 Burger H 75
 Bürki K 793
 Burns DJ 291
 Burris III HA 179, 347, 491
 Buser K 65
 Butow PN 189
 Buttitta F 695

Buzaid AC 827

C

Cabanillas F 157, 211, 1083

Caffo O 695

Caillet H 1065

Cairncross G 205

Caligara M 613

Calvi R 919

Cameron DA 409

Campanacci 864

Canellos GP S4: 91

Canepa C 719

Canevari S 227

Carbone GMR 659

Carde P 925

Carella AM S2: 1, 19

Carlier P S2: 19

Camino F 487

Carrato A 581

Carstairs K 1043

Cartoni C 1071

Cascinu S 538

Casella C 239

Casper ES 347

Cassidy J 208

Castellani A 538

Castiglione-Gertsch M 245, 471

Catalano G 538

Catapano CV 659

Catimel G 837

Cavalli F 7, 245, 471, 807, 1023

Cavanna L 537

Cavina R 640

Ceresa E 1023

Cerny T 793

Cerottini J-C 339

Cerutti I 719

Cervantes A 581

Chan WC S4: 41

Chandrashekar M 424

Chang J 671, 756

Chella A 747

Cheson BD 767

Chevallier B 165

Childs AM 189

Chimirri F S2: 19

Chollet P 1065

Christiansen H 183

Cianci C 601

Classen S 391

Clavel M 837

Coates AS 189, 245

Cocconi G 99, 433

Cognetti F 821, 867

Coiffier B 966

Colder CD 303

Collins CD 705

Collins DJ 47, 245

Colombo N 419

Colombo T 801

Combaret V 607

Connors TA 445

Conte PF 487, 601, 747, 857, 978

Conter V 725

Cooper MR 939

Cooper D 1029

Cormio G 271

Corrado C 719

Cortés-Funes H 245, S2: 1, S2: 23

Cosset JM 925

Cox J 157

Craze JL 89

Cremin P 745

Crescenti C S2: 19

Cripps MC 347

Crisi G 412

Crombez R 277

Crown J 405

Crowther D 705

Crump M 311, 1043

Cucchi M 919

Culine S 997

Cummings J 291

Cunningham D 47, 179, 277, 961

Cure H 575, 1065

Cvitkovic E 1065

Cwikiel M 731

D

D'Aprile M 821

D'Incalci M 725, 801

Dalesio O 139

Dalla Palma P 695

Daly PA 745

Dannecker C 391

Daus H S4: 35

de Boer CJ 251

de Bruijn HWA 511

de Bruijn KM 505

De Crescenzo A 919

de Graeff A 867

de Gramont A 95

de la Chapelle A 883

de Micheli R 487

de Mulder PHM 277, 521, 867

de Paoli A 537

de Placido S 821

de Pooter C 843

de Rijke JM 677

de Vries EGE 505, 511

de Wit R 1080

de Wynter E 1051, S2: 5

Decaudin D 925

Deerberg-Wittram J S4: 49

Dejana A S2: 19

del Valle ML 755

Del Ferro E 538

Delabie J S4: 41

Delfini R 1071

Deloche C 1065

Demicheli R 640

Dengra C 719

Denning-Kendall P S2: 47

Dent SF 561

Depierre A 945

Desai PB 355

Devi L 424

Dexter TM 1051

Dhermain F 925

Di Mola G 907

Di Palma M 525

Di Palma S 640

Díaz-Rubio E 95, 581, 643

Dicato M 277

Diehl V 397, S4: 1, 45, 61, 95, 109, 135

Diener P 65

Dieras V 165

Dingemans A-MC 625

Dirix LY 843

Dobson M 705

Dolensky J 637

Dombernowsky P 365, 687

Dominici C 607

Donaldson C S2: 47

Donati D 864

Dookeran KA 535

Doval DC 424

Dreef E 251

Dreyfus B 575

Drings P 139, 637

Drinkard LC 314

Droz JP 997

Drumea K 536

du Bois A 277

Duclos B 575

Dufour B 525

Dufour P 575

Dukoff R 103

Dullemond-Westland AC 505

Dumas F 575

Dunn SM 189

Duyster J S4: 19

E

Eberhardt W 55

Eckhardt JR 491

Eckhardt SG 491

Ecstein E 525

Edington H 535

Egger T 793

Eggermont AMM 317

Eghbali H 713

Einsele H 416

Eisenhauer E 205, 311, 561, 1077

El-Attar I 751

El-Said A 751

Ellis PM 189

Enander L-K 593

Engeler V 65

Engert A 397, S4: 1, 109, 135

Erley C 416

Errante D 233

Erttmann R 183, 607

Eskilsson J 731

Esteso A 173

Esteve J 607

Etienne M-C 283

Eton O 827

Extra YM 837

Eyal A 536

F

Fainsinger RL 855

Falcone A 601

Falkson CI 465

Falkson HC 465

Farber C 1083

Favrot MC 607

Federico M 619

Feine U 416

Feldman L 719

Fentiman IS 657

Fernandes DJ 659

Fernández I 719

Fernández-Martos C 581

Ferrari MG 619

Ferrari S 864

Fetscher S 871

Fey MF 121, 471, 758, 766, 953, 1086

Fibbe WE S2: 1, 15

Fields S 491

Figg WD 939

Findlay MPN 47

Fisher B 311, 1077

Fisher RI S4: 131, S6: 35

Flasshove M S2: 53

Flattery M 745

Flens MJ 75

Florio G S2: 19

Follath F 1059

Forbes JF 245

Forfang K 257

Forni C 864

Forni M 65

Fornier M 970

Forsyth P 205

Foss Abrahamsen A 145

Fossella FV 59

Fountzilas G 517

François E 95

Franklin J S4: 61

Franzén L 587

Frappaz D 607

Fraschini F 99

Frassoldati A 619

Frassoni F S2: 19

Freeman MB 151

Freilone R 919

Frickhofen N S4: 55

Fukuoka M 815

Fuller LM 157, 211

Fumoleau P 165

Furuse K 815

G

Gaafar R 751

Gabriele A 271, 861

Gad El-Mawla N 751

Gallamini A 919

Gallardo H S2: 53

Galligioni E 245

Gallino A 1059

Gallo C 821

Galloti P 487

Gallucci M 907

Gamba A 907

Gamelin E 95

Gamucci T 529

Garcia-Boyero R 322

Garcia JJ 719

García-Conde J 581

Gardin G 487

Gardiner J 409

Gasparini G 441, 695

Gastaburu J-J 95

Gause A S4: 35

Gebbia V 821

Gehl J 687

Gelber RD 245, 335

Gennari A 857, 978

Gentili D 725

Gentilini P 487

Ghio R 919

Giaccone G 35, 139, 625, 637

Giannopoulos A 644

Gieser PW 1009

Giordano M 537

Girinsky T 925

Girouard C 1043

Gisselbrecht C 966

Giulianotti PC 601

Glimelius B 593

Gnekow A 183

Goedhals L 945

Goey SH 317, 887

Goldman L 321

Goldhirsch A 65, 213, 245, 471, 801, 807

Goldstein D 1029

Golomb HM 314

Gonzalez Paz O 801

Gore M 179, 297

Grandi C 640

Graziano F 538

Green MR 347

Gregory RK 671, 756

Greiner R 65

Greiner TC 265

Gridelli C 821

Griesshammer M S4: 55

Griffin AM 189

Grise P 525

Griso L 919

Grogan TM S6: 3

Groisman GM 536

Gruss H-J S4: 19

Gudgeon A 245

Guerci A 966

Guex P 135, 645

Guillot T 283

Guzzo M 640

H

Hafner M S4: 55

Hagberg H 587

Hagemeister FB 157, 1083

Hager B 145

Haier B 397

Haim N 536

Hamza M-R 751

Hanauske AR 529

Hannisdal E 145

Hannoun L 173

Hansen HH 119, 365

Hansen M 365

Hansmann M-L S4: 27, 61

Haraf DJ 739, 913

Harper P 961

Hartrick A 31, 55, 1015

Hartmann F S4: 143

Hasenclever D S4: 95

Hassan R 103

Hauke RJ 265

Haupt A 1015

Hayat M 925

Hayungs J 55

Headlee D 939

Hebart H 416

Heesters MAAM 511

Heimpel H S4: 55

Heinz R 423

Hejna M 973

Helle P 139

Heneka M 755

Henriksson R 587

Henry-Amar M S4: 115

Herbrecht R 966

Hero B 183

Herrmann F 183, S4: 19
Herrmann R 551

Hess M 157
Hiddemann W 129
Higashi L 491
Hirsch FR 365
Hoekman K 35
Hoerni B 713
Hoffman K 593
Hoffman PC 314
Hohenberger P 197
Hollema H 511
Holmberg L 655
Holte H 145
Hong WK 59
Honkoop AH 35
Hopfinger G 423
Hoppe RT S4: 99, S4: 105
Horak ID 103
Hornedo J S2: 23
Horning SJ 115, S4: 105, S6: 21
Horwich A 989
Hoskins P 1077
Hossfeld DK 83
Houry S 173
Howell A 773, 1051
Hows J S2: 1, S2: 47
Hoy J 1029
Hsu Schmitz SF 793
Hubens G 843
Huber MH 59
Hughes MJ 208
Hummel M S4: 31
Hünerbein M 197
Husseini F 575

I

Ihlen H 257
Imrie K 1043
Incoronato P 821
Itzhaki M 95
Iveson A 47
Izrael V 173

J

Jackevicius A 637
Jacobsson G 593
Jager JJ 677
Jakobsson M 587
Jarrett AF S4: 5
Jayson G 705, 773
Jenkner A 607
Joffe J 297
Joly F S4: 115
Joss R 114
Juliéron M 925
Juliusson G 373, 1037
Jung W S4: 143

Jungi WF 65, 432, 471

K

Kalahanis N 644
Kantarjian H S6: 27
Kanz L 416, 755, 871, S2: 11
Kanzler H S4: 27
Kaplan EL 739
Karabelis A 517
Kaskas B 416
Katagami N 815
Kattis K 517
Kawahara M 815
Kaye SB 9, 208
Keating A 1043
Keating MJ S6: 27
Kennealey G 179
Kerbl R 607
Kerbrat P 165
Kerger J 867
Kermeis Y 966
Kerr DJ 208, 961
Kessinger A 151
Kester MGD 251
Khaled HM 751
Khayat D S2: 1, S2: 31
Kiani A 871
Kinuwaki E 815
Kiowski W 1059
Kirkpatrick A 139, 867
Kiss A 543
Klaassen U 55
Klingebiel T 183
Kluin-Nelemans JC 251
Kluin PM 251
Kohler D 939
Köhrmann O 1015
Köhrmann U 31
Kok TC 533
Kongerud J 257
König M 416
Koo WH 71
Koppejan AG 677
Komek G 973
Koscielny S 925
Kosmidis P 517
Koziner B 719
Krakowski Y 165
Kramar A 997
Krauss SA 314
Kristjansen PEG 365
Krüger W 83
Krzemieniecki K 977
Kuba M 815
Kube D 397
Kubota K 815
Kuhn JG 491
Küpper M S4: 35

Küppers R S4: 27
Kusminsky G 719
Kvaløy S 145

L

La Vecchia C 497
Labianca R 901
Lachter J 536
Lambert HE 361
Lampe C 755
Lampert F 183
Lan J 529
Langdon SP 291
Lange C 1051
Lange W 871
Langholm R 145
Langnas AN 265
Larregain D 525
Lassen U 365
Lastiri F 719
Latreille J 311
Leach MO 47
Lederlin P 966
Lee JS 59
Lee LE 409
Lefebvre JL 867
Legha SS 827
Lehnert M 529
Lencioni M 601
Lentz M-A 637
Leonard JP S2: 53
Leonard RCF 291, 409
Leonard T 409
Leonardi V 821
Lerma E S2: 19
Leszler A 575
Levi F 497
Levis A 919
Lewis C 1029
Leyvraz S 65
Licitra L 640
Liénard D 339
Ligi M 538
Lillemark J 373, 1037
Linch DC S2: 1, S2: 9
Lindtner J 245
Link H S2: 1, S2: 41
Linné T 593
Lippman SM 59
Lissoni A 271, 861
Loeffler M S4: 95
Loftin U S4: 35
Löhnert T 471
Lomberg H 587
Longo DL S4: 85
López JA 643
Lorigan PC 631
Losa G 861

- Losch M 55
 Lotz JP 173
 Lotze MT 535
 Lucas V 525
 Luft T 1051
 Lund MB 257
 Luporini G 901
 Luppi G 412
 Luppi M 619
 Lush RM 939
 Lusignani M 907

M
 Macdonald D 205
 Machover D 95
 Mackay J 291, 409
 Magrath I 751
 Manegold Ch 637
 Maneo A 271, 419, 801
 Manfrini M 864
 Mangioni C 419, 861
 Mann J 607
 Marafioti T S4: 31, S4: 61
 Marasca R 619
 Marchal G 871
 Marchetti A 695
 Margafiska K 977
 Marini G 245, 807
 Mark J S2: 15
 Martin C 575
 Martín M 643, 843
 Martinez Rolón J 719
 Marty M 95, 837
 Marx D 129
 Marzola M 419
 Masera G 725, 1005
 Massara G 919
 Massuti T 581
 Masters GA 314
 Masuo K 491
 Mathieu P 607
 Mauch PM S4: 79
 Maugard-Louboutin C 165
 Maurizi Enrici R 1071
 Mayer R 416
 Mayeur D 525
 McCann SR 745
 McClary KA 977
 McGregor K 208
 McLaughlin P 157, 211, 1083
 McQuade B 277, 945
 McRae J 277, 945
 McVie G 139
 Mead G 849
 Meerpohl HG 416
 Meloni G 933
 Ménard S 227
 Mercadante S 613

 Mercuri M 864
 Mermershtain W 321
 Meropol NJ 179
 Merran S 525
 Mertelsmann R 871
 Metzger G 95
 Metzner B 31
 Michail P 644
 Michelotti A 857
 Milano G 283
 Miller WR 291
 Milliken S 1029
 Milone G 719
 Milone J 719
 Mirimanoff RO 870
 Misra S 424
 Misset J-L 165
 Moleti ML 933
 Molinari R 640
 Montgomery GH 977
 Monzeglio C 487
 Moore MAS S2: 1, S2: 53
 Moore MJ 347
 Morgenstern GR 631
 Morrelli M 619
 Mosca F 601
 Mross K 83
 Müller-Weilrich St 183
 Munck JN 925
 Murray S 245
 Myers J 1083
 Mylonakis N 517

N
 N'Daw D 95
 Nagel S 953
 Nakai Y 815
 Natali M 821
 Negoro S 815
 Neijt JP 988
 Nelstrop AE 361
 Newell M 1029
 Newman RA 59
 Nicol A S2: 47
 Nieda M S2: 47
 Niedobitek G S4: 11
 Nieto Y 643
 Niitani H 815
 Nikou G 644
 Nome O 145, 257
 Nooter K 75
 Nooy M 505
 Nyman J 587
 Nyth AL 587

O
 O'Brien S S6: 27
 O'Reilly E 405

 Öberg K 453
 Oberlin O S4: 73
 Oberling F 575
 Oechslein E 1059
 Oguma T 491
 Olivares R 575
 Oliver I 961
 Olivier J-P 575
 Olver I 945
 Onetto N 1077
 Oostrum RG 75
 Orlandoni D 725
 Orsini E 933
 Orsucci L 919
 Oskam R 317
 Østerlind K 365
 Ottensmeier C 849

P
 Paaske T 687
 Pagani O 213
 Palazzolo G 821
 Palmeri S 821
 Pancera G 901
 Pantalony D 1043
 Papachristodoulou A 644
 Papadopoulos N 827
 Papargyriou J 644
 Parczewska J 977
 Paridaens R 277
 Parker L 607
 Parma G 419, 861
 Paska W 945
 Pate O 1083
 Patil PK 355
 Pavlidis N 517, 529
 Pavlovitch JM 525
 Pavlovsky S 719
 Pawinski A 637
 Pawlicki M 977
 Pazdur R 179
 Pedrinis E 1023
 Pelosio P 695
 Pepe R 821
 Perez-Manga G 961
 Perrone F 821
 Perrotta A 239
 Pesce G 807
 Petrini M 537
 Petruzella L 637
 Petti MC 933
 Pfanner E 601
 Pfeilstöcker M 423
 Pfister Ch 99
 Pfreundschuh M S4: 143, S4: 35
 Philip T 607
 Picci P 864
 Piccinini L 412

Pike J 1077
 Pinedo HM 35
 Pinto RM 933
 Piro LD S6: 41
 Pittelli MR 419
 Pittermann E 423
 Pittman K 297
 Plager C 827
 Planting AST 139, 755, 1080
 Pluda JM 939
 Podestà M S2: 19
 Polyzos A 644
 Portenoy RK 347
 Portlock C 1083
 Possinger K 391
 Postmus PE 303, 625
 Powell J 607
 Powles TJ 671, 756
 Pras E 511
 Prencipe E S2: 19
 Prendiville J 705
 Presta M 441
 Prevost G 575
 Price KN 245
 Prince HM 1043
 Pritchard J 89
 Proia A 1071
 Pronzato P 487
 Pujade-Lauraine E 525
 Pupa SM 227

R

Raderer M 973
 Radford JA 705, 793
 Rajewsky K S4: 27
 Randimbison L 497
 Ranson M 705
 Rao CR 424
 Råth U 961, 1015
 Raynaud F 47
 Recant W 739
 Reed E 939
 Regazzo C 907
 Regazzoni S 807
 Reifke J 83
 Renner C S4: 143
 Renninson J 705
 Resegotti L 919
 Reske SN S4: 55
 Reuß K S4: 109
 Reyes F 966
 Ricardi U 919
 Riccardi A 537
 Ricci S 601
 Richaud P 713
 Rifkin RM 265
 Rinaldi D 491
 Ring S 827

Ripamonti C 855
 Ritchie AA 291
 Riva A 165
 Rizzari C 725
 Robinson A 719
 Roche H 165
 Rodenhuis S 104
 Rodriguez G 491
 Rodriguez MA 157
 Roggero E 787, 1023
 Romaguera J 157
 Romero P 339
 Rosenberg SA 555, S4: 105
 Rosenstein DL 103
 Rossi A 821
 Rosso R 487
 Rota Scalabrini D 919
 Rota SM 271
 Rothenberg ML 347, 491
 Rubagotti A 239, 487
 Rubiales AS 755
 Rudenstam C-M 245
 Rüegg C 654
 Rufener B 793
 Rülfer J-U S4: 127
 Russo A 821
 Rustin GJS 361
 Rüter U 31

S

Sørensen JB 119
 Sadelain M S2: 53
 Sahin U S4: 143
 Sahmoud T 867
 Sakuma A 815
 Saletti P 213
 Salles G 993
 Salvadori B 857, 978
 Salvi F 919
 Samantas E 517
 Samsonov ME 535
 Samuels BL 314
 Sanna P 1023
 Santoro A 970
 Santosuosso A 907
 Sanz GF 322
 Sanz MA 322
 Sapia M 613
 Saporito G 719
 Sarris A 1083
 Sartor O 939
 Sastre J 95
 Savarino M 619
 Sawka C 205
 Scaglione F 99
 Scarffe JH 631
 Schabet M 755
 Schauer A 129

Scheding S S2: 11
 Scheithauer W 973
 Schellong G S4: 67
 Scheper RJ 75, 625
 Schijf CPT 521
 Schilf A 95
 Schilling F 607
 Schlegelberger B S4: 49
 Schlögl E 423
 Schmoll H-J 31, 1015
 Schnaars Y 637
 Schneider J 1059
 Schnell R S4: 135
 Schoeller T 855
 Schöffski P 1015
 Schornagel J 867
 Schouten HC 677
 Schouten LJ 677
 Schuurink E 251
 Scinto AF 821
 Scott G 1043
 Sebban C 966
 Secondo V 919
 See J 173
 Seiber S 55
 Seitz J-F 95, 945, 961
 Selby P 277, 297
 Sellström H 593
 Senn H-J 245, 471
 Serretta R 613
 Sessa C 8, 65, 213, 645, 801
 Sextro M S4: 61
 Seymour JF 157, 211
 Seymour L 179
 Shepherd FA 311
 Shuster JJ 1009
 Siderov J 41
 Sieber M S4: 127
 Siegenbeek van Heukelom L 505
 Sigsgaard TC 365
 Sikora SS 535
 Silingardi V 412
 Silvano G 747
 Simes J 41
 Singh R 671, 671
 Sjöden P-O 593
 Skacel Z 637
 Skarlos D 517
 Smetzer L 491
 Smir BN 265
 Smith B 297
 Smith IE 179, 771
 Smyth JF 211, 277, 529
 Soracco M S2: 19
 Sorbe B 587
 Soubeyran P 713
 Soukop M 208
 Southgate J 297

- Splinter TAW 533
 Sprangers MAG 381
 Srinivas V 424
 Stahl M 55
 Stavenow L 731
 Stein H S4: 31, S4: 61
 Stein ME 536
 Sternberg CN 878
 Stewart AK 277, 1043
 Stewart DJ 205, 311, 945
 Stiefel F 135, 645
 Stockman P 291
 Stornio A-M 347
 Stoter G 75, 317, 887, 1080
 Stuart G 1077
 Sudo K 491
 Sutcliffe S 1043
 Sutton DMC 1043
 Svensson C 593, 961
 Swan F 157
 Sweeney PJ 739
 Swenerton K 1077
 Swindell R 705, 1051
 Sylvester R 324
 Szabó BG 511
 Szendro G 321
 Sznol M 667
- T**
 Takada Y 815
 Tamburini M 907
 Tarassoff PG 347
 Tattersall MHN 189, 245
 Te VC 497
 Te Velde A 381, 529
 ten Bokkel Huinink WW 104
 Tesch H 397, S4: 109
 Testa NG 1051, S2: 1, S2: 5
 Thill L 575
 Thomson B 1029
 Thürlimann B 471
 Tibaldi C 747, 857
 Tidy VA 671
 Tilly H 966
 Tirelli U 233
 Tischler J 1015
 Tobler A 121, 953
 Tognoni A 857, 978
 Tomiak E 311
 Tondini C 970
 Torelli G 619
 Toscani F 907
 Toskas A 644
 Tourani JM 525
 Treleaven JG 671
 Trojani M 713
 Trümper L S4: 35
 Trunet PF 99
- Tsang R 1043
 Tschuempelin B 725
 Turina M 1059
 Tuxen MK 361
- U**
 Ucci G 537
 Uhr MR 646, 980
 Untereiner M 525
- V**
 Vaccher E 233
 Vaidya JS 355
 Valagussa P 221, 481
 Valbonesi M S2: 19
 Valsecchi MG 1005
 van Ark-Otte J 625
 van Cutsem E 871, 961
 van den Brandt PA 677
 van der Burg MEL 1080
 van der Gaast A 75, 533
 van der Graaf WTA 505
 van der Heul C 505
 van der Linden GHM 505
 van der Valk P 625
 van Glabbeke M 637
 van Groeningen CJ 35
 van Hoe L 871
 van Hoeff MEHM 1051
 van Hoesel QGCM 521
 van Krieken JHJM 251
 van Oosterom AT 843
 van Straelen D 277
 van Wingerden KE 75
 van Zandwijk N 637
 Vanhoef U 55
 Vannucci L 601
 Varette C 525
 Vassallo F S2: 19
 Veltri E 821
 Venturini M 487
 Verbeek W 31
 Verderio P 695
 Vergote I 871
 Verhagen CAHHVM 521
 Vermeulen PB 843
 Vermorken JB 35, 867
 Verweij J 277, 333, 529, 867, 887, 1080
 Vignetti M 933
 Vignoud J 95
 Vitolo U 919
 Vittrup Jensen B 687
 Vogel W S2: 11
 Vokes EE 15, 314, 739, 913
 von Bonin F S4: 35
 von Hoff DD 347, 491
 von Rohr A 793, 953
 Vorbeck F 973
- Vose JM 151, 265, S6: 13
 Vuillemin E 525
- W**
 Wagstaff J 35
 Wainman N 205
 Waldner R 423
 Watts MJ S2: 9
 Weaver A 705, S2: 5
 Weber-Mathiesen K S4: 49
 Weichselbaum RR 913
 Weinell P 183
 Weinlaender G 973
 Weiss G 491
 Weißbach L 31, 1015
 Wester M 59
 Westermann AM 104
 Westermann F 397
 Wiggers Th 317
 Wildiers J 867
 Wilke H 55
 Wilkinson JR 945
 Willems PHB 511
 Willemze R S2: 15
 Wils JA 211, 505
 Wolf J S4: 45
 Woodings PL 631
 Wrigley E 705
 Wymenga ANM 505
- Y**
 Yamori S 815
 Ychou M 95
 Yosef H 208
 Younes A 1083
- Z**
 Zalcberg JR 41, 179, 961
 Zambetti M 481
 Zander A 83
 Zanetta G 271, 861
 Zanoni A 864
 Zatloukal P 637
 Ziemann K S4: 31
 Zijlmans JM S2: 15
 Zobili A 412
 Zucca E 787, 793, 1023
 Zucchetti M 725, 801
 Zuehlendorf M 397
 Zwierzina H 667

